Research
Hormonal
Semaglutide 2.4 mg significantly improves control of eating, including craving control and craving for savory, sustained up to week 104, compared to placebo.
Semaglutide 2.4 mg helps you control your eating, including cravings for savory and sweet foods, with benefits sustained up to 104 weeks. This is achieved through once-weekly injections combined with lifestyle changes.
GoodSupportsHIGH confidence
There were significant improvements in all Control of Eating questionnaire domains (craving control, craving for savory, craving for sweet, and positive mood) up to week 52 with semaglutide treatment versus placebo, with improvements in craving control and craving for savory remaining significantly different at week 104.
Why this rating
Based on exploratory endpoint analysis in a subgroup of STEP 5, consistent with previous studies.
Source
Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program
Patrick M. O’Neil et al. · Postgraduate Medicine · 2022
DOI 10.1080/00325481.2022.2150006
narrative_reviewCited 18×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Once-weekly subcutaneous semaglutide 2.4 mg significantly improves weight-related quality of life (IWQOL-Lite-CT) and health-related quality of life (SF-36v2) compared to placebo in adults with overweight or obesity, independent of the magnitude of weight loss in some domains.Good
- Semaglutide 2.4 mg treatment leads to preferential loss of fat mass over lean body mass, which supports improvements in physical function and walking capacity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →